Drug Trial Radar · NCT06970405
Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women
Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
May 29, 2025
Primary completion
Jun 8, 2026
Study completion Jun 8, 2026
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- May 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on otherwise healthy participants with obesity. The aim of the study is to see how safe and tolerable the study drug is. The study is looking at several other research questions, including: * How much study drug is in the blood at different times * What effect the study drug has on the blood clotting * What effect the study drug has on hormone levels * What effect the study drug has on some organs that produce hormones * What effect hormones have on the side effects produced by the study drug * Whether the body makes antibodies against the study drug (which could change how well the drug works or could lead to side effects)
Conditions
- Obesity
Interventions
GaretosmabDrug
Administered per the protocol
Matching PlaceboDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs)Time frame: Through Week 32
- Severity of TEAEsTime frame: Through Week 32
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.